Terms and Conditions:
Cancer Research UK Prizes
# Table of Contents

1  Introduction.......................................................................................................................... 3  
   1.1  Definitions .................................................................................................................... 3  

2  Terms and Conditions............................................................................................................. 4  
   2.1  Cancer Research UK Lifetime Achievement in Cancer Research Prize ....................... 4  
   2.2  Cancer Research UK Future Leaders Prize ................................................................... 6  
   2.3  Cancer Research UK Translational Cancer Research Prize ........................................... 7  
   2.4  Cancer Research UK Jane Wardle Prevention and Early Diagnosis Prize ..................... 9
INTRODUCTION

Cancer Research UK has established four Prizes to recognise outstanding achievement or promise in cancer research in the UK. The four Prizes are: Lifetime Achievement in Cancer Research, Future Leaders, Translational Cancer Research and the Jane Wardle Prevention and Early Diagnosis Prize.

The Prizes will be funded by the Gibb Research Fellowship Endowment Fund. The objects of the Fund are “for the provision and maintenance of fellowships and/or studentships for research into the clinical aspects of cancer or into such other aspects as the Trustees shall decide.”

The Trustees of the Fund have approved the use of the Fund’s monies to finance the Prizes established by Cancer Research UK, together with any associated expenditure, and confirmed such use is within the Fund’s permitted objects. The intention of each Prize is to raise awareness of cancer research in the UK, stimulate research, encourage young scientists at the start of their careers and draw attention to the activities of Cancer Research UK and the Recipients of the Prizes within the scientific community.

1.1 Definitions

**Fund**
The Gibb Research Fellowship Endowment Fund.

**Prize or Prizes**
One of the four Cancer Research UK Prizes identified in the Introduction to this document, which recognise outstanding achievement or promise in cancer research in the UK, or collectively all four. The term ‘Prize’ may refer to a specific one of the Prizes, as the context requires.

**Recipient**
The recipient of each of the Prizes, as recommended annually by the Prizes selection panel and approved by the Scientific Executive Board of Cancer Research UK.

**Primary Recipient**
For the Translational Cancer Research Prize, the first-named person on the nomination form, who will have obtained the agreement of all of the nominated Team members to represent the Team throughout the award process and take responsibility for the administration of the Prize.

**Team**
The nominated individuals for the Translational Cancer Research Prize.

**Host Institution**
The university or other institution at which a Recipient is based.
2 TERMS AND CONDITIONS OF CANCER RESEARCH UK PRIZES

These Terms and Conditions apply only to the administration of the Prizes awarded to the Recipients. The criteria for nominations for the Prizes, the detailed eligibility of the Prize nominees, the composition, Terms of Reference and operation of the Prizes selection panel, and the decision making process, are all governed by separate guidelines and terms and conditions. These are available from Cancer Research UK1. In all matters relating to the eligibility, nomination and decision-making processes, the most current published guidelines and terms and conditions will take precedence over any information contained in this document.

All Recipients and their Host Institutions must abide by the Terms and Conditions of these Prizes and, in the case of the Translational Cancer Research Prize, Cancer Research UK’s Grant Conditions, as amended from time to time.

The Prizes will be presented at the Annual NCRI Cancer Conference following the decision of the selection panel and the Scientific Executive Board of Cancer Research UK. All Recipients will be expected to attend the NCRI Conference to receive their Prizes.

Until the presentation is made, all information about the Recipients of the Prizes, and about unsuccessful nominations, is confidential.

Cancer Research UK, the NCRI and the Fund may share such confidential information among themselves and, without further reference to the Recipients or their Host Institutions, use information about the Prizes and Recipients, including photographs, information provided as part of the nomination and other publishable information held about the Recipients, in their publicity, marketing and fund-raising activities.

Cancer Research UK may make reasonable requests of the Recipients to support the work of Cancer Research UK through participation in advisory committees, consultations, working groups or other means. Recipients should, where possible, support Cancer Research UK in these ways.

2.1 Cancer Research UK Lifetime Achievement in Cancer Research Prize

The purpose of the Prize
This Prize will honour an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether they have been in research, leadership, or mentorship, will have had a lasting impact on the cancer field and will have demonstrated a lifetime commitment to progress against cancer.

No more than one Prize will be awarded in any one year.

1 Please see: http://science.cancerresearchuk.org/funding/find-grant/browse-by-funding-type/research-prizes/
Summary of eligibility for the Prize

- Nominations may be made on behalf of individuals who are living at the time of the nomination. An individual cannot nominate himself/herself.
- Nominees need not be in receipt of, or have been supported either directly or indirectly by, Cancer Research UK funding.
- While the current geographical location of the Nominee does not affect their eligibility a significant proportion of their research output should have arisen from work performed in the UK academic sector (such as a university or a charity-funded or other non-profit research institute).
- The Prize will be presented to an individual investigator.
- Institutions or organisations are not eligible for the Prize.

The components of the Prize
The Lifetime Achievement Prize will comprise:

- An honorarium of £25,000
- Free registration, travel and accommodation at the next Annual NCRI Cancer Conference following the decision to award the Prize
- A commemorative trophy

The Recipient will be expected to give a plenary lecture at a subsequent Annual NCRI Cancer Conference, the date and timing of which shall be at the discretion of the NCRI Cancer Conference Programme Planning Committee.

The Recipient will also be expected to write a review article for the British Journal of Cancer to coincide with the timing of the award of the Prize. The exact timing and topic will be at the discretion of the journal editors.

There is no requirement for the Recipient to acknowledge the receipt of the Prize, or the Fund, in subsequent publications. However, the Recipient should acknowledge the Prize when submitting biographies for the remainder of their academic career. The Recipient should use the full title of the Award at all times, and refer to themselves as a holder of the Cancer Research UK Lifetime Achievement in Cancer Research Prize.

The honorarium
The honorarium will be paid in a single instalment. It will be deposited in a bank account of the Recipient’s choosing, the details of which should be forwarded to Cancer Research UK before the date of the presentation ceremony.

This is a personal Prize, awarded in recognition of the Recipient’s outstanding contribution to his or her field of cancer research. Recipients are not required to report on how they have spent the money. However, the following restrictions on the use of the money will apply:

1. The money should be used to support the Recipient’s future research, to further their research career or otherwise support activities undertaken in a professional capacity. The funds may be used for the Recipient themselves or for other researchers in their field.

2. The money may not be spent in a way that is contrary to the vision and purpose of Cancer Research UK, or brings Cancer Research UK or the Fund into disrepute. In particular, Recipients must abide by Cancer Research UK’s Code of Practice on Tobacco Industry Funding to Universities.
Cancer Research UK’s understanding is that a prize which is unsolicited, and which is awarded as a mark of honour, distinction or public esteem in recognition of outstanding achievement in a particular field, including the field in which the Recipient operates professionally, is not chargeable to UK tax. However, it is the responsibility of the Recipient to clarify their personal tax situation with their relevant tax authorities. Cancer Research UK or the Fund will not offer advice on the tax implications of the Prize.

2.2 Cancer Research UK Future Leaders Prize

The purpose of the Prize
This Prize will recognise the impact of research carried out by an early career scientist, that is, one who has been awarded a PhD within the last 10 years. It is expected that the Recipient will have produced international quality research, and be able to demonstrate the ambition and aspirations consistent with the potential to achieve world-leading status.

Up to three Prizes will be awarded in any one year.

Summary of eligibility for the Prize
- Nominees must, on 31 May of the year of the Prize, be within 10 years of having been awarded a PhD or MD.
- Nominees should have produced international quality research outputs, a significant proportion of which should arise from work performed in the UK.
- An individual cannot nominate himself/herself
- Nominees need not be in receipt of, or have been supported either directly or indirectly by, Cancer Research UK funding.
- The Prize will be presented to an individual investigator.

The components of the Prize
The Future Leaders Prize will comprise:
- An honorarium of £10,000
- Free registration, travel and accommodation at the next Annual NCRI Cancer Conference following the decision to award the Prize
- A commemorative trophy

There is no requirement for the Recipient to acknowledge the receipt of the Prize, or the Fund, in subsequent publications. However, the Recipient should acknowledge the Prize when submitting biographies for a period of at least five years following the receipt of the Prize. The Recipient should use the full title of the Prize at all times, and refer to themselves as a holder of the Cancer Research UK Future Leaders Prize.

If more than one Prize is made, there shall be no ranking or hierarchy between the Prizes and the Recipients.

The honorarium
The honorarium will be paid in a single instalment. It will be deposited in a bank account of the Recipient’s choosing, the details of which should be forwarded to Cancer Research UK before the date of the presentation ceremony.

This is a personal Prize, awarded in recognition of the Recipient’s existing impact on his or her research field and his or her outstanding potential for future contributions. Recipients are not
required to report on how they have spent the money. However, the following restrictions on the use of the money will apply:

1. The money should be used to support the Recipient’s future research, to further their research career or otherwise support activities undertaken in a professional capacity. The funds may be used for the Recipient themselves or for other researchers in their field.

2. The money may not be spent in a way that is contrary to the vision and purpose of Cancer Research UK, or brings Cancer Research UK or the Fund into disrepute. In particular, Recipients must abide by Cancer Research UK’s Code of Practice on Tobacco Industry Funding to Universities.

Cancer Research UK’s understanding is that a prize which is unsolicited, and which is awarded as a mark of honour, distinction or public esteem in recognition of outstanding achievement in a particular field, including the field in which the Recipient operates professionally, is not chargeable to UK tax. However, it is the responsibility of the Recipient to clarify their personal tax situation with their relevant tax authorities. Cancer Research UK and the Fund will not offer advice on the tax implications of the Prize.

2.3 Cancer Research UK Translational Cancer Research Prize

The purpose of the Prize
This Prize will recognise important translational research achievements in the continuing effort to prevent and cure cancer and to recognize and reward cancer scientists for these extraordinary accomplishments. The Prize will be made to an outstanding Team that has made seminal cancer research discoveries at the cutting edge of scientific novelty and significance. Such discoveries must have accelerated progress against cancer and must have implications for future discoveries and contributions to cancer research. Team members do not necessarily need to be at the same Institution or even in the same country, although at least one major member of the team must have carried out their work in the UK.

No more than one Prize will be awarded in any one year.

Eligibility for the Prize
For the purpose of this Prize, a Team will comprise researchers providing complementary interdisciplinary expertise, each of whom has made separate substantive and quantifiable contributions to the research being recognised.

Team members may be working within the same institution or at several institutions; not restricted to those in the UK. However, a significant proportion of the work that is being honoured must have been carried out in the UK.

If Team members are in the same Host Institution, they must have clearly separate funding and research space or in the case of a large research group be clearly part of separate teams.

The research to be recognised should reflect work towards a specific scientific goal that otherwise would not be realised by any single component of the Team.

Nominations are open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the
world. Such institutions include those in academia, industry, or government. Teams comprising academic and industry researchers will be accepted.

The components of the Prize
The Translational Cancer Research Prize will comprise:

- A grant of £25,000
- Free registration, travel and accommodation at the next Annual NCRI Cancer Conference following the decision of the selection panel, for the Primary Recipient and up to four other members of the Team
- A commemorative trophy

The Prize grant
A grant of £25,000 will be made to the Primary Recipient, as named in the nomination for the Prize. The grant may be used in any way that supports the ongoing cancer research, cancer medicine, or cancer-related biomedical science of the members of the Team, or will otherwise support cancer research at the Host Institutions of the Team members.

The grant will be subject to Cancer Research UK’s Grant Conditions, with some amendments as detailed in this document.

The Primary Recipient will be deemed to be the Principal Investigator for the grant, as defined by Cancer Research UK’s standard grant management processes.

The Prize money will be awarded as a single grant, in a single instalment, to one Host Institution. The transfer of funds to the Host Institutions of other Team members is acceptable, but is the responsibility of the Team members and their Host Institutions.

The grant will be issued for five years. At the end of that period, the grant will be subject to Cancer Research UK’s reconciliation procedures and any unspent money will be reclaimed.

The use of the Prize grant
The members of the Team are entirely responsible for deciding how the grant will be allocated between members of the Team and what the Prize money will be used for. The Team is not required to inform or ask permission from Cancer Research UK as to how the grant shall be used. However, the Principal Recipient must present evidence to Cancer Research UK that all members of the Team are in agreement with the planned administration of the Prize money, and that all members are content that the Primary Recipient will be Principal Investigator for the grant and responsible for the administration of the grant.

In the event that the Primary Recipient moves to a new Host Institution, the grant may either transfer to another member of the Team or move with the Primary Recipient to their new Host Institution. In the event of the retirement or death of the Primary Recipient during the period of the grant, the grant will be transferred to another member of the Team at their current Host Institution. In any of these cases, Cancer Research UK will require evidence that all members of the Team are content with the new arrangements.

The grant may be used for any purpose that is consistent with the normal purchasing and recruitment rules of the Host Institution. This could include, but is not restricted to, salaries, research running expenses, equipment, student fees and travel.
The Prize grant may be used in part or in full to establish a fund from which further prizes, bursaries or grants may be awarded. Under these circumstances, the Team will not be required to spend all the money within the five-year period of the grant. However, the Primary Recipient shall notify Cancer Research UK of their intention and submit a copy of the conditions under which awards will be made from the fund.

There is no requirement for the Recipients to acknowledge the receipt of the Prize in their subsequent publications. However, the Recipients should acknowledge the Prize when submitting biographies for five years following the receipt of the Prize. The Recipients should use the full title of the Prize at all times, and refer to themselves as a holder of the Cancer Research UK Translational Cancer Research Prize.

Any publications arising from research work or individuals funded by the Prize grant should acknowledge the support of Cancer Research UK Translational Cancer Research Prize.

2.4 Cancer Research UK Jane Wardle Prevention and Early Diagnosis Prize

The purpose of the Prize
This Prize will honour an individual at any career stage who has produced international quality research in the field of prevention or early detection of cancer.

No more than one Prize will be awarded in any one year.

Summary of eligibility for the Prize
- Nominees should work in the broad research field relating to prevention or early detection of cancer.
- Nominees must have produced international quality research outputs, and be committed to building their research career within the UK.
- An individual cannot nominate himself/herself.
- Nominees need not be in receipt of, or have been supported either directly or indirectly by, Cancer Research UK funding.
- The Prize will be presented to an individual investigator.

The components of the Prize
The Jane Wardle Prevention and Early Diagnosis Prize will comprise:
- An honorarium of £10,000
- Free registration, travel and accommodation at the next Annual NCRI Cancer Conference following the decision to award the Prize
- A commemorative trophy

There is no requirement for the Recipient to acknowledge the receipt of the Prize, Cancer Research UK or the Fund, in subsequent publications. However, the Recipient should acknowledge the Prize when submitting biographies for a period of at least five years following the receipt of the Prize. The Recipient should use the full title of the Prize at all times, and refer to themselves as a holder of the Cancer Research UK Jane Wardle Prevention and Early Diagnosis Prize.

The honorarium
The honorarium will be paid in a single instalment. It will be deposited in a bank account of the Recipient’s choosing, the details of which should be forwarded to Cancer Research UK before the date of the presentation ceremony.
This is a personal Prize, awarded in recognition of the Recipient’s existing impact on his or her research field and his or her outstanding potential for future contributions. Recipients are not required to report on how they have spent the money. However, the following restrictions on the use of the money will apply:

1. The money should be used to support the Recipient’s future research, to further their research career or otherwise support activities undertaken in a professional capacity. The funds may be used for the Recipient themselves or for other researchers in their field.

2. The money may not be spent in a way that is contrary to the vision and purpose of Cancer Research UK, or brings Cancer Research UK or the Fund into disrepute. In particular, Recipients must abide by Cancer Research UK’s Code of Practice on Tobacco Industry Funding to Universities.

Cancer Research UK’s understanding is that a prize which is unsolicited, and which is awarded as a mark of honour, distinction or public esteem in recognition of outstanding achievement in a particular field, including the field in which the Recipient operates professionally, is not chargeable to UK tax. However, it is the responsibility of the Recipient to clarify their personal tax situation with their relevant tax authorities. Cancer Research UK and the Fund will not offer advice on the tax implications of the Prize.